Alcobra Ltd. Ord (ADHD) 5.10 $ADHD Alcobra Ltd. to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 8:15 AM

Alcobra Ltd. Ord (ADHD) 5.10 $ADHD

Alcobra Ltd. to Participate in Upcoming Investment Conferences
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3 Annual Healthcare Day.
ADHD: 5.10 (-0.13)

Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:30AM CDT
Alcobra Ltd (ADHD) was a big mover last session, as the company saw its shares rise over 6% on the day.
ADHD: 5.10 (-0.13), JNP: 6.91 (-0.06)

The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
Zacks Equity Research - Zacks Investment Research - Mon May 16, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
SNDX: 13.17 (-0.41), EDIT: 30.54 (-1.85), ADHD: 5.10 (-0.13), MCRB: 33.53 (+0.86), NEOS: 9.83 (+0.14)

Alcobra reports 1Q loss
Automated Insights - Mon May 16, 7:15AM CDT
TEL AVIV, Israel (AP) _ Alcobra Ltd. (ADHD) on Monday reported a loss of $5.1 million in its first quarter.
ADHD: 5.10 (-0.13)

Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 16, 7:00AM CDT
-- Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 5.10 (-0.13)

Drug Stocks' Earnings to Watch on May 16: ADHD, MCRB & More
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:26AM CDT
What's in store for drug stocks, Alcobra, Seres and others when they report their first-quarter results on May 16?
SNDX: 13.17 (-0.41), EDIT: 30.54 (-1.85), ADHD: 5.10 (-0.13), MCRB: 33.53 (+0.86), NEOS: 9.83 (+0.14)

Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16
GlobeNewswire - Wed May 04, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
ADHD: 5.10 (-0.13)

MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 5.10 (-0.13), MEIP: 1.39 (-0.02)

Falling Earnings Estimates Signal Weakness Ahead for Valeant Pharmaceuticals (VRX)
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:53AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
VRX: 24.14 (-1.34), ADHD: 5.10 (-0.13)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 5.10 (-0.13), REPH: 8.27 (-0.20)

What Falling Estimates & Price Mean for Lannett (LCI)
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:40AM CDT
Lannett has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
LCI: 23.21 (-0.90), ADHD: 5.10 (-0.13)

Alcobra (ADHD) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:34AM CDT
Alcobra Ltd. (ADHD) has been struggling lately, but the selling pressure may be coming to an end soon
ADHD: 5.10 (-0.13)

Grab These 4 Incredible Momentum Stocks for Less Than $10
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 9:10AM CDT
Momentum investing grants success to those who can effectively ride the upswing and brave the downswing of the market with the same elan.
PRMW: 11.20 (+0.06), ADHD: 5.10 (-0.13), VSLR: 3.19 (-0.09), MDXG: 7.88 (-0.10)

Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 5.10 (-0.13), OHRP: 2.87 (-0.11)

AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 3.19 (-0.16), GILD: 84.45 (-1.32), ADHD: 5.10 (-0.13)

Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 3.97 (-0.03), ADHD: 5.10 (-0.13)

Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 5.10 (-0.13), ANAC: 99.17 (+0.09)

Ironwood's Q4 Loss Narrower than Expected, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 10:12AM CST
Ironwood Pharmaceuticals, Inc. (IRWD) reported a narrower-than-expected loss of 10 cents per share in the fourth quarter of 2015.
AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13), ADHD: 5.10 (-0.13), PETX: 6.70 (-0.40)

New Strong Buy Stocks for February 19th
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
BLIN: 1.14 (+0.03), AMBR: 6.88 (+0.03), ADHD: 5.10 (-0.13), CPB: 62.70 (+0.19), BCO: 29.48 (-0.39)

ArQule (ARQL) Shows Strength: Stock Adds 7.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 7:15AM CST
ArQule Inc. (ARQL) shares rose almost 8% in the last trading session.
ADHD: 5.10 (-0.13), ARQL: 1.78 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cognizant Boosts Claude AI with 25,000 Pro Workforce

Moving AI from Theory to Practice You know, AI isn't about just keeping up with the hype; it's about shoving those algorithms right where they can do the most good—right at the core of business operations. And that’s precisely what Cognizant's cooking up with their fresh-off-the-press Claude Frontier Capability Group. They’ve thrown more than 25,000 pros into the...

Hexnode XDR Expands Threat Detection, MacOS Support

Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

Gen Z, Millennials Lean on AI Amid Fiscal Crunch

AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...

International Tower Hill's Q3 Results: Gold Updates

An Eye on International Tower Hill's Latest Moves You've got International Tower Hill Mines (TSX: ITH, NYSE American: THM) laying their cards on the table for the third quarter. This ain't just any routine check-in—it's a glimpse at their Livengood Gold Project, standing tall on the promise of gold beyond the horizon. A cool $106 million in cash? Not too shabby, folks....

A Gentle Stake: Colts Neck's Rural Fight Ahead

By Ryan Hughes Updated Nov 10, 2026 Category News Views 101

Michael Fazio's Gambit in Colts Neck If you're not fired up about land deals, you should be now. Michael Fazio, the owner of Synergy Stables in Colts Neck, New Jersey, is laying his cards on the table with a proposition for preserving the integrity of the township's rural landscape. Rather than cashing in on monstrous offers for high-density housing, Fazio's plan involves...

From Vätternrundan to Göta Canal: Circularity in Action

Sustainability in Action: Vätternrundan Leads the Way Ever thought your banana peel could contribute to cultural heritage? That’s the twist here. Vätternrundan 2026 hit the mark by turning food waste into a natural asset along the Göta Canal. It's a glimpse of the future where waste isn't a by-product but a resource. Transforming Waste into Growth In a world where...

1-800Accountant Secures Global Win in Tax Services

Another Feather in the Cap for 1-800Accountant You don’t get to be at the top of your game without turning a few heads. And 1-800Accountant has done just that, snagging the Fall 2026 Clutch Global Award for their expertise in the accounting universe. The Importance of Listening In this day and age, businesses large and small are realizing that the voice of the client is...

Enghouse Acquires MIND CTI: Strategic Telecom Play

Enghouse's Strategic Move into Telecom You want a real shake-up in the telecom space? Here it is. Enghouse Systems Limited (TSX: ENGH) is stepping up its game by acquiring MIND C.T.I. Ltd. (NASDAQ: MNDO). This cash-only transaction is tailored to broaden Enghouse’s suite of offerings in telecom and enterprise unified communications (UC). The price? A neat US$1.30 per...

Freedom Motors USA Appoints Joost de Vries as CEO

Shifts in the Auto World Forget the fact that the family car comes with a couple of new cupholders—over at Freedom Motors USA, they're shaking things up with a CEO change. Nothing says "we mean business" quite like bringing in Joost de Vries to lead the charge into a new era. With this move, Freedom Motors is clearly aiming for bold growth in the sphere of accessible...